Jyong Biotech Ltd. (MENS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Jyong Biotech Ltd. (MENS) trades at $2.16 with AI Score 46/100 (Grade C). Jyong Biotech Ltd. is a Taiwan-based biopharmaceutical company specializing in the development of plant-derived drugs for urinary system diseases. Market cap: $164M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for MENS: MENS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MENS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MENS: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Jyong Biotech Ltd. (MENS) Healthcare & Pipeline Overview
Jyong Biotech Ltd., based in Taiwan, focuses on developing and commercializing plant-derived drugs for urinary system diseases, with key assets including MCS-2 in Phase III trials for BPH and PCP in Phase II trials for prostate cancer, positioning them in the competitive biotechnology landscape.
What Is the Investment Thesis for MENS?
Jyong Biotech Ltd. presents a focused investment opportunity within the biotechnology sector, specifically targeting urinary system diseases. The company's lead drug candidate, MCS-2, is in Phase III clinical trials for BPH, representing a near-term value driver. Positive trial outcomes and subsequent commercialization could significantly boost revenue. The PCP drug candidate in Phase II for prostate cancer offers further potential upside. However, the company's high beta of 8.47 indicates substantial volatility. Key catalysts include the progression of MCS-2 through Phase III trials and the advancement of PCP through Phase II. Successful clinical trial results and regulatory approvals are critical for realizing the company's potential. The absence of a dividend reflects a focus on reinvesting earnings into research and development. Investors should monitor clinical trial data, regulatory milestones, and competitive developments in the BPH and prostate cancer treatment landscapes. The company's relatively small size and focused pipeline present both opportunities and risks.
Based on FMP financials and quantitative analysis
MENS Key Highlights
MCS-2 is in Phase III clinical trials for the treatment of BPH, representing a near-term potential revenue driver.
- PCP is in Phase II clinical trials for prostate cancer, offering further potential upside in the oncology space.
- The company operates through subsidiaries like Health Ever Bio-Tech and Genvace, enhancing its research and development capabilities.
- Jyong Biotech focuses on plant-derived drugs, potentially offering a unique selling proposition in the pharmaceutical market.
- The company's beta of 8.47 indicates high volatility, reflecting the inherent risks associated with biotechnology investments.
Who Are MENS's Competitors?
MENS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CELC Celcuity Inc. | $90.57 | -3.29% | $4.42B | 54 |
| CGON CG Oncology Inc | $77.61 | -3.81% | $6.85B | — |
| CNTA Centessa Pharmaceuticals plc | $40.50 | +0.00% | $6.27B | 52 |
| LEGN Legend Biotech Corporation | $21.26 | -5.93% | $3.93B | 32 |
| APGE Apogee Therapeutics, Inc. | $134.75 | +0.03% | $8.34B | 70 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MENS's Key Strengths?
Focus on plant-derived drugs provides a unique selling proposition.
- MCS-2 in Phase III trials represents a near-term value driver.
- PCP in Phase II trials offers potential upside in the oncology space.
- Experienced management team with expertise in drug development.
What Are MENS's Weaknesses?
Limited financial resources compared to larger pharmaceutical companies.
- High beta indicates significant volatility.
- Reliance on a small number of drug candidates.
- Geographic concentration in Taiwan.
What Could Drive MENS Stock Higher?
Completion of Phase III clinical trials for MCS-2 in the next 1-2 years.
- Advancement of PCP into later-stage clinical trials within 2-3 years.
- Potential strategic partnerships or licensing agreements within the next 2-3 years.
- Continued research and development efforts to expand the drug pipeline.
- Monitoring of regulatory landscape and potential changes in approval processes.
What Are the Key Risks for MENS?
Financial-distress signal — its Altman Z-Score of -2.06 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for MCS-2 or PCP.
- Unfavorable clinical trial results for drug candidates.
- Competition from established pharmaceutical companies with greater resources.
- High beta indicates significant volatility in stock price.
- Changes in the regulatory landscape could impact drug development and approval processes.
What Are the Growth Opportunities for MENS?
- Successful Completion of MCS-2 Phase III Trials: The successful completion of Phase III clinical trials for MCS-2, targeting BPH, represents a significant growth opportunity. This milestone could be achieved within the next 1-2 years, driving significant revenue growth.
- Advancement of PCP into Later-Stage Trials: The progression of PCP, the drug candidate for prostate cancer, into later-stage clinical trials offers another key growth avenue. Positive results in Phase II could pave the way for Phase III trials and eventual market approval. The prostate cancer treatment market is substantial, and a successful drug could generate significant revenue streams for Jyong Biotech within 3-5 years.
- Expansion of Pre-clinical Pipeline: Jyong Biotech's pre-clinical program, IC, targeting other urinary system diseases, provides a longer-term growth opportunity. Successful development and clinical trials could expand the company's product portfolio and address unmet medical needs in the urinary disease space. This expansion could materialize over the next 5-7 years.
- Strategic Partnerships and Licensing Agreements: Forming strategic partnerships with larger pharmaceutical companies or securing licensing agreements for its drug candidates could accelerate Jyong Biotech's growth. These collaborations could provide access to additional funding, expertise, and distribution channels, enhancing the company's ability to commercialize its products on a global scale. Such partnerships could be forged within the next 2-3 years.
- Geographic Expansion into New Markets: Expanding its geographic presence beyond Taiwan into other Asian markets, Europe, and North America represents a significant growth opportunity. This expansion would require regulatory approvals and strategic market entry strategies, but could substantially increase the company's revenue potential. This expansion could begin within the next 3-5 years, contingent on clinical trial success and regulatory approvals.
What Are MENS's Competitive Advantages?
- Proprietary plant-derived drug formulations.
- Patents protecting their drug candidates.
- Clinical trial data demonstrating efficacy and safety.
- Regulatory approvals granting market exclusivity.
What Does MENS Do?
Jyong Biotech Ltd., headquartered in New Taipei City, Taiwan, is a biotechnology company dedicated to the research, development, and commercialization of innovative plant-derived drugs aimed at addressing urinary system diseases. Founded with the vision of leveraging natural resources for therapeutic solutions, Jyong Biotech operates through its subsidiaries, including Health Ever Bio-Tech and Genvace, to advance its drug pipeline. The company's primary focus is on developing treatments for conditions such as benign prostatic hyperplasia (BPH) and prostate cancer. Jyong Biotech's lead drug candidate, MCS-2, is currently in Phase III clinical trials for the treatment of BPH. This plant-derived drug aims to provide relief from the symptoms associated with BPH, a common condition affecting aging men. The company's second most advanced drug candidate, PCP, is in Phase II clinical trials for prostate cancer. Additionally, Jyong Biotech has a pre-clinical program, IC, targeting other urinary system diseases. The company's strategic approach involves rigorous scientific research, clinical trials, and strategic partnerships to bring its innovative therapies to market. With a team of 31 employees, Jyong Biotech is committed to improving the lives of patients suffering from urinary system diseases through its plant-derived drug development programs. Jyong Biotech aims to establish itself as a key player in the biotechnology sector by focusing on innovative treatments derived from natural sources.
What Products and Services Does MENS Offer?
- Develop plant-derived drugs for urinary system diseases.
- Conduct clinical trials for drug candidates like MCS-2 (BPH) and PCP (prostate cancer).
- Operate through subsidiaries like Health Ever Bio-Tech and Genvace.
- Focus on treatments for conditions like benign prostatic hyperplasia (BPH) and prostate cancer.
- Engage in research and development to expand their drug pipeline.
- Seek regulatory approvals for their drug candidates.
- Commercialize approved drugs in the market.
How Does MENS Make Money?
- Develop and patent plant-derived drug formulations.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from health authorities.
- Manufacture and commercialize approved drugs, either directly or through partnerships.
What Industry Does MENS Operate In?
Jyong Biotech operates within the biotechnology industry, a sector characterized by high growth potential and significant investment in research and development. The market for urinary system disease treatments, including BPH and prostate cancer, is substantial and growing, driven by an aging population and increasing awareness of these conditions. The competitive landscape includes both established pharmaceutical companies and smaller biotech firms, such as CELC: Celcuity Inc., CGON: CG Oncology Inc, CNTA: Centessa Pharmaceuticals plc, LEGN: Legend Biotech Corporation, and APGE: Apogee Therapeutics, Inc., all vying for market share. Jyong Biotech's focus on plant-derived drugs offers a potential niche in this competitive environment.
Who Are MENS's Key Customers?
- Patients suffering from urinary system diseases, such as BPH and prostate cancer.
- Healthcare providers who prescribe and administer the company's drugs.
- Hospitals and clinics that use the company's products.
- Pharmaceutical distributors who distribute the company's drugs.
Key Financial Metrics
Return on equity for Jyong Biotech Ltd. stands at 19.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -22.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.45 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -2.9%, the inverse of the P/E and a quick read on earnings relative to price.
Jyong Biotech Ltd. (MENS) Valuation Context
Valued at $164M, MENS is classified as a micro-cap stock. Relative to its peer group, MENS's quantitative score of 46/100 is roughly in line with the peer average of 52/100.
Company Profile
Jyong Biotech Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New Taipei City, TW. The company is led by CEO Fu-Feng Kuo. MENS has traded publicly since 2025.
Financial Health
Jyong Biotech Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.06 places it in the distress zone, a signal of elevated financial risk.
MENS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see long-term value, even if the market hasn't caught on yet.
- The community is buzzing about potential partnerships, indicating strong belief in the company's strategic direction.
- Despite recent market volatility, there's a palpable sense that Jyong Biotech is undervalued compared to its peers.
- Positive chatter about upcoming product releases fuels optimism that the company is on the verge of a breakthrough.
Bear Case
- Insider activity isn't always a reliable signal; sometimes it's just executives exercising options or diversifying holdings.
- Community sentiment can be fickle, easily swayed by short-term news cycles and hype, as seen with meme stock frenzies.
- Market perception can be slow to adjust, and the company might face headwinds in proving its worth relative to established players.
- Product release delays or negative trial results could quickly sour the positive outlook, similar to what happened with many COVID-19 vaccine hopefuls.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MENS Latest News
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Jun 29, 2026
MENS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MENS.
Price Targets
Wall Street price target analysis for MENS.
MENS MoonshotScore
What does this score mean?
The MoonshotScore rates MENS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Fu-Feng Kuo
CEO
Fu-Feng Kuo is the Chief Executive Officer of Jyong Biotech Ltd. He leads a team of 31 employees, driving the company's strategic direction and overseeing the development of its plant-derived drug pipeline. His background includes extensive experience in the biotechnology sector, with a focus on pharmaceutical development and commercialization. He has a strong understanding of the regulatory landscape and clinical trial processes, essential for navigating the complexities of bringing new drugs to market. His prior roles involved managing research teams and overseeing clinical studies.
Track Record: Under Fu-Feng Kuo's leadership, Jyong Biotech has advanced its lead drug candidate, MCS-2, into Phase III clinical trials for BPH. He has also overseen the progression of PCP into Phase II trials for prostate cancer. His strategic decisions have focused on leveraging the company's expertise in plant-derived drugs and building a strong pipeline of innovative therapies. He has successfully navigated the company through various funding rounds and established key partnerships to support its growth.
What Investors Ask About Jyong Biotech Ltd. (MENS) — Healthcare
What does the AI Score mean for MENS?
MENS holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Jyong Biotech Ltd. is a Taiwan-based biopharmaceutical company specializing in the development of plant-derived drugs for urinary system diseases. Their pipeline includes drug candidates in Phase …
What does Jyong Biotech Ltd. Ordinary Shares do?
Jyong Biotech Ltd. is a Taiwan-based biopharmaceutical company focused on developing and commercializing plant-derived drugs for urinary system diseases. Their primary focus is on treatments for conditions such as benign prostatic hyperplasia (BPH) and prostate cancer. The company's lead drug candidate, MCS-2, is in Phase III clinical trials for BPH, while PCP is in Phase II trials for prostate cancer.
What do analysts say about MENS stock?
As of 2026-05-10, analyst coverage of Jyong Biotech Ltd. Ordinary Shares (MENS) is limited. Key valuation metrics are still developing due to the company's stage of clinical development. Growth considerations center on the successful completion of clinical trials for MCS-2 and PCP, as well as potential regulatory approvals. Investors should closely monitor clinical trial data and regulatory milestones.
What are the main risks for MENS?
The main risks for Jyong Biotech Ltd. include the potential failure to obtain regulatory approvals for its drug candidates, particularly MCS-2 and PCP. Unfavorable clinical trial results could also significantly impact the company's prospects. Competition from established pharmaceutical companies with greater resources poses an ongoing challenge. The company's high beta indicates significant volatility in its stock price.
What are the key factors to evaluate for MENS?
Jyong Biotech Ltd. (MENS) holds an AI score of 46/100 (low). presents a focused investment opportunity within the biotechnology sector, specifically targeting urinary system diseases. Not financial advice.
How frequently does MENS data refresh on this page?
MENS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MENS's recent stock price performance?
Jyong Biotech Ltd. (MENS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on plant-derived drugs provides a unique selling proposition. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MENS overvalued or undervalued right now?
Jyong Biotech Ltd. (MENS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MENS before investing?
Before investing in Jyong Biotech Ltd. (MENS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage may impact the accuracy of certain data points.
- The biotechnology sector is inherently risky, and investments may be subject to significant volatility.